Navigation Links
Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
Date:2/20/2008

PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to announce its 2007 fourth quarter and year-end results on Tuesday, February 26, 2008 by press release after the financial markets close.

Following the release, Medarex's management will host a conference call and live webcast at 4:30 p.m. Eastern Time. To access the call live, please dial 1-866-510-0710 (U.S./Canada) or 1-617-597-5378 (international) and enter passcode number 15176024. The webcast can be accessed through the Investor Relations section of Medarex's website at http://www.medarex.com and will be archived for 14 days following the webcast.

A telephonic replay of the conference call will be available until midnight Eastern Time, March 4, 2008. Access numbers for this replay are 1-888-286-8010 (U.S./Canada) or 1-617-801-6888 (international); passcode number 75836084.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over thirty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces Completion of Sale of Shares in Genmab A/S
2. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
3. Medarex Announces Election of Marc Rubin as New Board Member
4. Medarex to Present at the UBS Global Life Sciences Conference
5. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
6. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
7. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
8. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... EDISON, N.J. , Feb. 4, 2016 ... company focused on the development and commercialization of targeted ... BIO CEO & Investor Conference 2016, to be held ... and Source Capital Group,s 2016 Disruptive Growth & Healthcare ... on February 10-11, 2016. James Sapirstein ...
(Date:2/4/2016)... , February 4, 2016 ... Laboratories (ABL), Inc. --> Strasbourg, France ... --> PharmaVentures is pleased to announce that it ... its biopharmaceutical manufacturing unit in Strasbourg, France ... --> --> Transgene (Euronext: ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... a new office dedicated to the North American healthcare market. , Aerocom Healthcare, ... healthcare facilities. The company will provide new pneumatic tube systems or expand ...
Breaking Biology Technology:
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
Breaking Biology News(10 mins):